Key takeaways
- 400-500 patients in the National Amyloidosis Centre's ATTRv surveillance registry, the deepest UK evidence base available to any pre-launch sponsor
- ~800 patients tracked in the separate UK National ATTRv Registry, led by UCL and Queen Elizabeth Hospital Birmingham
- ~30 active NHS Tc-PYP scintigraphy centres nationally, the diagnostic referral endpoint for every named UK ATTR KOL
- 6 KOL Mapping gates (K1-K6), each independently verified before a name enters the workbook
The National Amyloidosis Centre holds NICE's clinical-expert seat at every ATTR appraisal to date, evidence of how concentrated UK ATTR amyloidosis expertise actually is.
UK ATTR amyloidosis expertise concentrates around a small number of named institutions, not a broad national specialist base. The National Amyloidosis Centre, based at UCL and the Royal Free and led by Professor Hawkins, is NICE's appointed clinical expert for every ATTR technology appraisal to date, from TA984 (tafamidis) through TA1121 (acoramidis). NAC also runs a family-cascade and pre-symptomatic ATTRv surveillance registry covering 400-500 patients under monitoring, the deepest evidence base available to any pre-launch sponsor. Our KOL Universe gate (K1) starts by mapping exactly this kind of institutional weight before any single physician is scored.
That structure runs alongside a second, distinct registry. The UK National ATTRv Registry, led jointly by UCL and Queen Elizabeth Hospital Birmingham, tracks approximately 800 hereditary ATTR patients nationally, a separate cohort from NAC's pre-symptomatic surveillance population. Diagnosis itself runs through roughly 30 active NHS Tc-PYP scintigraphy centres, the referral endpoint for every HFpEF and increased-wall-thickness case flagged on echo. Our Tier Classification gate (K2) scores named clinical-expert roles like NAC's against registry leadership and scintigraphy-centre affiliation, alongside a strict verification standard: no named individual enters the workbook without a Verified, Industry benchmark, or Requires client validation tag, and this workbook adds no named individual beyond Professor Hawkins, who is already on the record in AXLRx's UK ATTR Launch-Readiness assessment.
The UK ATTR amyloidosis KOL structure — one clinical-expert centre, one registry, thirty scintigraphy sites
| Institution | Role | Scale |
|---|---|---|
| National Amyloidosis Centre (UCL/Royal Free) | NICE's appointed clinical-expert centre for every ATTR appraisal to date; led by Professor Hawkins | 400-500-patient ATTRv surveillance registry |
| UK National ATTRv Registry (UCL + Queen Elizabeth Hospital Birmingham) | National hereditary ATTR registry, distinct from NAC's surveillance cohort | ~800 patients tracked |
| NHS Tc-PYP scintigraphy network | Diagnostic referral endpoint for ATTR-CM confirmation nationally | ~30 active centres |
Sources: National Amyloidosis Centre annual report; NICE TA984 and TA1121 evidence submissions (clinical-expert testimony); UK National ATTRv Registry (UCL/Queen Elizabeth Hospital Birmingham).
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Which UK institutions hold the clinical-expert weight that shapes every NICE ATTR appraisal, and how concentrated is that structure? • The National Amyloidosis Centre's clinical-expert role across TA984 and TA1121 • institutional concentration as a KOL-tiering signal • K1 KOL Universe Sizing methodology
- How does AXLRx distinguish NAC's ATTRv surveillance registry from the separate UK National ATTRv Registry when tiering scientific influence? • K2 Tier Classification methodology • registry leadership and scintigraphy-centre affiliation as scoring inputs • K3 Scientific Influence methodology
- What verification standard applies before Professor Hawkins or any other named individual ships in the workbook? • The three-tag verification protocol (Verified/Industry benchmark/Requires client validation) • why this workbook adds no new named individual beyond what AXLRx has already published • live institutional-affiliation cross-checks
What's inside
-
1 · The Binding Constraint 2 pp
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against NAC's NICE clinical-expert role before the rest of the workbook is built out
-
2 · KOL Universe (K1) 4 pp
- Every UK ATTR amyloidosis KOL sized and sourced from NICE appraisal records, registry leadership, and institutional-affiliation data
- The National Amyloidosis Centre and the UK National ATTRv Registry as the sizing anchors
- Universe boundaries: who counts as a KOL versus a high-volume prescribing cardiologist
-
3 · Tier Classification (K2) 3 pp
- Scientific-influence scoring across NICE clinical-expert roles, registry leadership, and Tc-PYP scintigraphy-centre affiliation
- What separates a Tier 1 KOL from a high-volume community cardiologist
-
4 · Scientific Influence (K3) 3 pp
- Influence inputs: NICE appraisal testimony, registry authorship, institutional role
- Cross-checked against independent NICE evidence-submission data
-
5 · Engagement Readiness (K4) 3 pp
- Readiness scoring and channel recommendations per KOL
- Sequencing implications for MSL deployment
-
6 · MSL Territory Coverage (K5) 3 pp
- Territory-to-KOL coverage map across NHS Tc-PYP scintigraphy centres nationally
- Where current MSL deployment has gaps
-
7 · Cross-Border Network (K6) 3 pp
- Multi-market reach for KOLs active beyond the UK, across Europe and international ATTR networks
- Implications for coordinated versus purely local engagement
-
8 · Client Alignment Questions 2 pp
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom workbook delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging UK ATTR amyloidosis specialists. Custom workbook in 72 hours.
- 1. Submit your requestSpecify your indication, geography, and institution scope.
- 2. Scoping callAXLRx analyst confirms institution scope and verification standard before building.
- 3. DeliveryResearch-verified KOL workbook in 72 hours with optional analyst readout.
How AXLRx builds this workbook
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx KOL workbook is built from live NICE appraisal records, registry publications, and institutional-affiliation data, not secondary summaries. No KOL name ships without a verification tag.
UK ATTR amyloidosis KOL sources: NICE TA984 and TA1121 evidence submissions naming the National Amyloidosis Centre as clinical expert, the National Amyloidosis Centre's published ATTRv surveillance registry data, and the UK National ATTRv Registry (UCL and Queen Elizabeth Hospital Birmingham).
- National Amyloidosis Centre's clinical-expert role verified against NICE TA984 and TA1121 evidence submissions
- ATTRv surveillance registry patient count (400-500) verified against NAC's published registry data
- UK National ATTRv Registry patient count (~800) verified against UCL/Queen Elizabeth Hospital Birmingham registry publications
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Deliverables What formats are included with every workbook?
Every commissioned KOL Mapping workbook includes an editable 6-sheet Excel workbook (KOL Universe, Tier Scoring, Engagement Calendar, MSL Territory, Cross-Border Network, Evidence Register) and a PDF summary brief. No PowerPoint deck — this deliverable is built to be worked in directly. An optional 45-minute analyst readout call is included.
Sources How are KOL identities and rankings verified?
Every KOL entry is built from live NICE appraisal records, registry publications, and institutional-affiliation data, then tagged Verified, Industry benchmark, or Requires client validation. No name ships unverified.
Customisation Can I scope this to a specific institution set or region?
Yes. The intake form captures your indication, geography, and institution scope. A scoping call confirms scope before research starts. Commission via the intake form to start.